Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

著者: J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair, Stephanie Korn, Ken Ohta, Marek Lommatzsch, Gary T. Ferguson, William W. Busse, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Viktoría Werkström, Magnus Aurivillius, Mitchell Goldman - The Lancet 2016 被引用: 1,379